Pricing updated 2019-07-18. Prices are subject to change without notice.
VR23 is a chloroquine (Item No. 14194) derivative that functions as a proteasome inhibitor (IC50s = 1 nM, 50-100 nM, and 3 µM for trypsin-like, chymotrypsin-like, and caspase-like proteasomes, respectively).1 It also deregulates the activity of cyclin E and other centrosomal proteins, resulting in the induction of multiple centrosome amplification, abnormal spindle formation, uneven cytokinesis, irreversible mitotic arrest, and eventually apoptosis that is specific to cancer cells.1 In combination with the chymotrypsin-like proteasome inhibitor bortezomib (Item No. 10008822), VR23 can produce a synergistic effect in killing multiple myeloma cells, including those that are resistant to bortezomib.1
Warning - this product is not for human or veterinary use.
View the Cayman Structure Database for chemical structure definitions for many Cayman products
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.
Pundir, S., Vu, H.Y., Solomon, V.R., et al. VR23: A quinoline-